pamidronate has been researched along with Osteonecrosis in 119 studies
Osteonecrosis: Death of a bone or part of a bone, either atraumatic or posttraumatic.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years." | 9.14 | Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. ( Abildgaard, N; Ahlberg, L; Andersen, NF; Carlson, K; Dahl, IM; Fayers, P; Gimsing, P; Gluud, C; Gregersen, H; Hjorth, M; Hjorth-Hansen, H; Juliusson, G; Knudsen, LM; Linder, O; Mylin, A; Nesthus, I; Nielsen, JL; Turesson, I; Vangsted, A; Waage, A; Westin, J; Wisløff, F, 2010) |
| "To assess outcomes of young patients with osteonecrosis (ON) treated with pamidronate in terms of relief of pain, prevention of progress and bony collapse of involved area." | 9.12 | Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes. ( Nguyen, T; Zacharin, MR, 2006) |
| " In 2002, 9 months after the intravenous bisphosphonate zoledronic acid received regulatory approval for marketing, the FDA received reports of nine patients with cancer, who were treated with zoledronic acid, who unexpectedly developed osteonecrosis of the jaw." | 8.84 | Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. ( Bennett, CL; Boyd, I; Carson, K; Dimopoulos, M; Edwards, BJ; Farrugia, M; Gounder, M; Marx, R; McKoy, JM; Mehta, J; Migliorati, C; Obadina, E; Raisch, DW; Ruggiero, S; Singhal, S; Trifilio, S; West, D, 2008) |
| "Few reports have investigated medication-related osteonecrosis of the jaws (MRONJ) in the pediatric population." | 8.12 | Medication-Related Osteonecrosis of the Jaws in the Pediatric Population. ( Neal, TW; Schlieve, T, 2022) |
| "Patients with medication-related osteonecrosis of the jaw (MRONJ) are at risk for developing infections and often require long-term antimicrobial therapy for management." | 7.83 | Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws. ( Glotzbecker, B; Mawardi, H; Richardson, P; Woo, SB, 2016) |
| "A total of 18 cases of osteonecrosis were recorded in the group administered pamidronate and dexamethasone." | 7.76 | An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. ( Camacho-Alonso, F; Gómez-García, F; López-Jornet, P; Molina-Miñano, F; Vicente-Ortega, V, 2010) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 7.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "Bisphosphonate-associated osteonecrosis of the jaw (BON) is mainly observed in patients with multiple myeloma, and to a lesser extent in breast and prostate cancer patients receiving intravenous treatment with potent bisphosphonates." | 7.75 | [Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma]. ( Abildgaard, N; Gregersen, H; Lund, T; Marker, P; Vangsted, A, 2009) |
| " Histopathologic examination correlated well with CT and MRI, which are the choice for the evaluation of bisphosphonate-associated jawbone osteonecrosis." | 7.74 | Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. ( Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A, 2008) |
| "We report on our experience with 13 cases of jaw osteonecrosis in patients treated with amino-bisphosphonates." | 7.74 | Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. ( Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH, 2008) |
| " The purpose of this study was to determine the incidence of jaw necrosis among a homogeneous population of multiple myeloma patients receiving the bisphosphonate pamidronate, to investigate risk factors and comorbidities that increase the risk and to characterize the radiographic changes on conventional dental radiographs in terms of type and frequency." | 7.74 | A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. ( Jadu, F; Lee, L; Pharoah, M; Reece, D; Wang, L, 2007) |
| "Bisphosphonate use, in particular pamidronate, improved pain scores, analgesic requirement and musculoskeletal function in patients with osteonecrosis occurring as a complication of childhood ALL therapy." | 5.14 | Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). ( Carter, T; Cole, C; Kotecha, RS; Lee, SJ; Murray, KJ; Powers, N, 2010) |
| " Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years." | 5.14 | Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. ( Abildgaard, N; Ahlberg, L; Andersen, NF; Carlson, K; Dahl, IM; Fayers, P; Gimsing, P; Gluud, C; Gregersen, H; Hjorth, M; Hjorth-Hansen, H; Juliusson, G; Knudsen, LM; Linder, O; Mylin, A; Nesthus, I; Nielsen, JL; Turesson, I; Vangsted, A; Waage, A; Westin, J; Wisløff, F, 2010) |
| "To assess outcomes of young patients with osteonecrosis (ON) treated with pamidronate in terms of relief of pain, prevention of progress and bony collapse of involved area." | 5.12 | Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes. ( Nguyen, T; Zacharin, MR, 2006) |
| "Zoledronic acid and pamidronate are two potent anticatabolic nitrogen-containing bisphosphonates (BPs) used extensively in diseases with high bone turnover such as multiple myeloma (MM)." | 4.87 | The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. ( Pozzi, S; Raje, N, 2011) |
| " In 2002, 9 months after the intravenous bisphosphonate zoledronic acid received regulatory approval for marketing, the FDA received reports of nine patients with cancer, who were treated with zoledronic acid, who unexpectedly developed osteonecrosis of the jaw." | 4.84 | Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. ( Bennett, CL; Boyd, I; Carson, K; Dimopoulos, M; Edwards, BJ; Farrugia, M; Gounder, M; Marx, R; McKoy, JM; Mehta, J; Migliorati, C; Obadina, E; Raisch, DW; Ruggiero, S; Singhal, S; Trifilio, S; West, D, 2008) |
| "Few reports have investigated medication-related osteonecrosis of the jaws (MRONJ) in the pediatric population." | 4.12 | Medication-Related Osteonecrosis of the Jaws in the Pediatric Population. ( Neal, TW; Schlieve, T, 2022) |
| "Patients with medication-related osteonecrosis of the jaw (MRONJ) are at risk for developing infections and often require long-term antimicrobial therapy for management." | 3.83 | Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws. ( Glotzbecker, B; Mawardi, H; Richardson, P; Woo, SB, 2016) |
| "We studied markers of bone turnover over a 6-month period after a single dose of zoledronic acid in 29 patients with multiple myeloma in remission who previously received 8 to 12 doses of pamidronate or zoledronate (NCT00577642)." | 3.80 | Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. ( Anderson, KC; Ghobrial, IM; Laubach, JP; Munshi, NC; Nemani, N; Patel, CG; Raje, NS; Richardson, PG; Santo, L; Schlossman, RL; Scullen, TA; Yee, AJ, 2014) |
| "Osteonecrosis of the jaw is an adverse outcome associated with bisphosphonate treatment." | 3.79 | Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study. ( Catalfamo, L; Centofanti, A; Cutroneo, G; De Ponte, FS; Favaloro, A; Runci, M; Siniscalchi, EN, 2013) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 3.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "A total of 18 cases of osteonecrosis were recorded in the group administered pamidronate and dexamethasone." | 3.76 | An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. ( Camacho-Alonso, F; Gómez-García, F; López-Jornet, P; Molina-Miñano, F; Vicente-Ortega, V, 2010) |
| " Osteonecrosis of the jaw is an uncommon but serious event in patients receiving monthly intravenous bisphosphonates or denosumab." | 3.76 | Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. ( Aapro, M; Costa, L; Saad, F, 2010) |
| "These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw." | 3.76 | Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010) |
| "Bisphosphonate-associated osteonecrosis of the jaw (BON) is mainly observed in patients with multiple myeloma, and to a lesser extent in breast and prostate cancer patients receiving intravenous treatment with potent bisphosphonates." | 3.75 | [Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma]. ( Abildgaard, N; Gregersen, H; Lund, T; Marker, P; Vangsted, A, 2009) |
| "Cases of osteonecrosis of the jaw (ONJ) have been reported with an increasing frequency over the past 5 years." | 3.74 | Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. ( Bohle, GC; Carlson, DL; Estilo, CL; Farooki, A; Fornier, M; Halpern, JL; Huryn, JM; Lwin, PT; Riedel, ER; Schoder, H; Tunick, SJ; Van Poznak, CH; Wiliams, T; Zhou, Q, 2008) |
| " The purpose of this study was to determine the incidence of jaw necrosis among a homogeneous population of multiple myeloma patients receiving the bisphosphonate pamidronate, to investigate risk factors and comorbidities that increase the risk and to characterize the radiographic changes on conventional dental radiographs in terms of type and frequency." | 3.74 | A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. ( Jadu, F; Lee, L; Pharoah, M; Reece, D; Wang, L, 2007) |
| "We report on our experience with 13 cases of jaw osteonecrosis in patients treated with amino-bisphosphonates." | 3.74 | Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. ( Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH, 2008) |
| " Histopathologic examination correlated well with CT and MRI, which are the choice for the evaluation of bisphosphonate-associated jawbone osteonecrosis." | 3.74 | Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. ( Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A, 2008) |
| "Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid." | 3.73 | Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. ( Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E, 2005) |
| " We present two patients with multiple myeloma who developed osteonecrosis of the jaws on intravenous treatment with zolendronic acid and pamidronate, respectively." | 3.73 | [Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis]. ( Gregersen, H; Neumann, B, 2006) |
| " Recently, zoledronate and pamidronate have been linked to osteonecrosis of the jaw, specially after surgical dental procedures." | 3.73 | [Osteonecrosis associated with the use of biphosphonates: Case report]. ( Agurto P, J; Anguita C, T; Laissle C, G; Roa E, I, 2006) |
| "Recently, some reports indicate that osteonecrosis of the jaws could occur after taking drugs containing hisphosphonates, including alendronate, pamidronate and zolendronate, which are widely used to treat osteoporosis and metastatic skeletal lesions in clinic." | 3.73 | [Advances in the research of bisphosphonate-associated osteonecrosis of the jaws]. ( Ji, T; Ruan, M; Zhang, CP, 2006) |
| " The preliminary results seem to suggest that biphosphonate-associated osteonecrosis can be well controlled by a nonsurgical protocol consisting in long-term administration of antibiotics." | 2.73 | Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. ( Felicetti, L; Gissi, DB; Marchetti, C; Montebugnoli, L; Pelliccioni, GA; Pizzigallo, A, 2007) |
| "Pamidronate disodium-associated bone necrosis is poorly understood at the cellular and molecular levels." | 1.46 | Pamidronate Disodium Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells In Vitro. ( Li, Z; Mai, H; Sun, J; Xu, Y; Yang, X; Yu, Y, 2017) |
| "Comparative analysis of different cancer patients helps the treating oncologist/dentist to identify patients with a more imminent risk to develop an ONJ (i." | 1.42 | Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. ( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015) |
| "In this cohort study, patients with multiple myeloma (MM) on intravenous BP therapy were enrolled over 1 year." | 1.37 | Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. ( Burkley, B; Casanova, O; Ferreira, P; Gong, Y; Hou, W; Katz, J; Langaee, TY; Moreb, JS; Salmasinia, D, 2011) |
| "The patient had a medical history of breast cancer with bone metastasis that was treated by chemotherapy with 45 mg pamidronate in 2 weekly courses for 16 months." | 1.36 | [A case of breast cancer with extensive osteonecrosis of maxilla induced by a bisphosphonate]. ( Inokuchi, S; Koga, C; Koga, M; Kusukawa, J; Tanaka, Y; Yokomizo, Y, 2010) |
| "Recent cases of bone necrosis of the jaws have been associated with the use of bisphosphonate therapy." | 1.35 | Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management. ( Fayans, EP; Grewal, VS, 2008) |
| "Patients with breast cancer demonstrated a reduced risk for ONJ development, which turned out to be nonsignificant after adjustment for other variables." | 1.35 | Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. ( Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K, 2009) |
| "Recent cases of bone necrosis of the jaws have been associated with the use of bisphosphonate therapy." | 1.35 | Bisphosphonate-associated osteonecrosis. A clinician's reference to patient management. ( Fayans, EP; Grewal, VS, 2008) |
| "In this study, cancer patients who had received zoledronate exhibited a significant 30-fold increase in their risk to develop ONJ." | 1.35 | Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. ( Dodson, TB; Wessel, JH; Zavras, AI, 2008) |
| "Pamidronate has been studied as a therapeutic drug for various osteopenic diseases." | 1.34 | Inhibition of bone healing by pamidronate in calvarial bony defects. ( Cho, BO; Cho, M; Choi, JY; Kim, HJ; Kim, SG; Lee, YC; Seong, HS, 2007) |
| "Multiple myeloma was the most common comorbidity." | 1.34 | Bisphosphonates and jaw osteonecrosis: the UAMS experience. ( Anaissie, EJ; Boyette, J; Clarke, BM; Stack, BC; Suen, JY; Vural, E, 2007) |
| " Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure." | 1.34 | Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. ( Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007) |
| " Current reports have focused on therapy-resistant osteonecrosis of the jaws as a possible side effect of bisphosphonates." | 1.33 | [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates]. ( Eufinger, H; Hoefert, S, 2005) |
| "Over last 10 years, cases of jaw bone necrosis have been associated with the use of bisphosphonate therapy." | 1.33 | Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. ( Corradi, D; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P, 2005) |
| "The reasons for bisphosphonate treatment were multiple myeloma in 12 patients, breast cancer with bone metastasis in four patients and histiocytosis X in one patient." | 1.33 | Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. ( Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A, 2006) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| "Here we report 29 cases of bone necrosis of the jaws in patients treated with pamidronate (Aredia), zoledronate (Zometa) and alendronate: 15 underwent surgical procedures and 14 occurred spontaneously." | 1.33 | Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. ( Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 80 (67.23) | 29.6817 |
| 2010's | 37 (31.09) | 24.3611 |
| 2020's | 2 (1.68) | 2.80 |
| Authors | Studies |
|---|---|
| Neal, TW | 1 |
| Schlieve, T | 1 |
| de Souza Tolentino, E | 1 |
| de Castro, TF | 1 |
| Michellon, FC | 1 |
| Passoni, ACC | 1 |
| Ortega, LJA | 1 |
| Iwaki, LCV | 1 |
| da Silva, MC | 1 |
| Bostrom, B | 1 |
| Xu, Y | 1 |
| Sun, J | 1 |
| Yang, X | 1 |
| Yu, Y | 1 |
| Mai, H | 1 |
| Li, Z | 1 |
| Owosho, AA | 1 |
| Liang, STY | 1 |
| Sax, AZ | 1 |
| Wu, K | 1 |
| Yom, SK | 1 |
| Huryn, JM | 2 |
| Estilo, CL | 2 |
| Lee, KC | 1 |
| Ferguson, BM | 1 |
| Terpos, E | 3 |
| Morgan, G | 1 |
| Dimopoulos, MA | 2 |
| Drake, MT | 1 |
| Lentzsch, S | 1 |
| Raje, N | 2 |
| Sezer, O | 1 |
| García-Sanz, R | 1 |
| Shimizu, K | 1 |
| Turesson, I | 2 |
| Reiman, T | 1 |
| Jurczyszyn, A | 1 |
| Merlini, G | 1 |
| Spencer, A | 1 |
| Leleu, X | 1 |
| Cavo, M | 1 |
| Munshi, N | 1 |
| Rajkumar, SV | 2 |
| Durie, BG | 2 |
| Roodman, GD | 1 |
| De Ponte, FS | 2 |
| Favaloro, A | 1 |
| Siniscalchi, EN | 1 |
| Centofanti, A | 1 |
| Runci, M | 1 |
| Cutroneo, G | 1 |
| Catalfamo, L | 1 |
| Patel, CG | 1 |
| Yee, AJ | 1 |
| Scullen, TA | 1 |
| Nemani, N | 1 |
| Santo, L | 1 |
| Richardson, PG | 2 |
| Laubach, JP | 1 |
| Ghobrial, IM | 1 |
| Schlossman, RL | 1 |
| Munshi, NC | 1 |
| Anderson, KC | 1 |
| Raje, NS | 1 |
| Gabbert, TI | 1 |
| Hoffmeister, B | 1 |
| Felsenberg, D | 1 |
| Mawardi, H | 2 |
| Glotzbecker, B | 1 |
| Richardson, P | 1 |
| Woo, SB | 5 |
| Amin, NL | 1 |
| James, RM | 1 |
| Phillips, R | 1 |
| Aarabi, S | 1 |
| Draper, L | 1 |
| Grayson, B | 1 |
| Gurtner, GC | 1 |
| La Verde, N | 1 |
| Bareggi, C | 1 |
| Garassino, M | 1 |
| Borgonovo, K | 1 |
| Sburlati, P | 1 |
| Pedretti, D | 1 |
| Bianchi, C | 1 |
| Perrone, S | 1 |
| Mihali, D | 1 |
| Cobelli, S | 1 |
| Mantica, C | 1 |
| Rizzo, A | 1 |
| Farina, G | 1 |
| Van Poznak, CH | 1 |
| Wiliams, T | 1 |
| Bohle, GC | 1 |
| Lwin, PT | 1 |
| Zhou, Q | 1 |
| Riedel, ER | 1 |
| Carlson, DL | 1 |
| Schoder, H | 1 |
| Farooki, A | 1 |
| Fornier, M | 1 |
| Halpern, JL | 1 |
| Tunick, SJ | 1 |
| Grewal, VS | 2 |
| Fayans, EP | 2 |
| Chahine, C | 1 |
| Cheung, MS | 1 |
| Head, TW | 1 |
| Schwartz, S | 1 |
| Glorieux, FH | 1 |
| Rauch, F | 1 |
| Young, P | 1 |
| Finn, BC | 1 |
| Bruetman, JE | 1 |
| Edwards, BJ | 1 |
| Gounder, M | 1 |
| McKoy, JM | 1 |
| Boyd, I | 1 |
| Farrugia, M | 1 |
| Migliorati, C | 1 |
| Marx, R | 1 |
| Ruggiero, S | 1 |
| Dimopoulos, M | 1 |
| Raisch, DW | 1 |
| Singhal, S | 1 |
| Carson, K | 1 |
| Obadina, E | 1 |
| Trifilio, S | 1 |
| West, D | 1 |
| Mehta, J | 1 |
| Bennett, CL | 1 |
| Alons, K | 1 |
| Kuijpers, SC | 1 |
| de Jong, E | 1 |
| van Merkesteyn, JP | 1 |
| Lund, T | 1 |
| Gregersen, H | 3 |
| Vangsted, A | 2 |
| Marker, P | 1 |
| Abildgaard, N | 2 |
| Geusens, P | 1 |
| Lazarovici, TS | 1 |
| Yahalom, R | 1 |
| Taicher, S | 1 |
| Elad, S | 1 |
| Hardan, I | 1 |
| Yarom, N | 1 |
| Stanton, DC | 1 |
| Balasanian, E | 1 |
| Seehra, J | 1 |
| Sloan, P | 1 |
| Oliver, RJ | 1 |
| Stockmann, P | 2 |
| Hinkmann, FM | 1 |
| Lell, MM | 1 |
| Fenner, M | 2 |
| Vairaktaris, E | 1 |
| Neukam, FW | 1 |
| Nkenke, E | 2 |
| O'Ryan, FS | 1 |
| Khoury, S | 1 |
| Liao, W | 1 |
| Han, MM | 1 |
| Hui, RL | 1 |
| Baer, D | 1 |
| Martin, D | 1 |
| Liberty, D | 1 |
| Lo, JC | 1 |
| Hoefert, S | 2 |
| Schmitz, I | 1 |
| Tannapfel, A | 1 |
| Eufinger, H | 2 |
| Vahtsevanos, K | 2 |
| Kyrgidis, A | 1 |
| Verrou, E | 2 |
| Katodritou, E | 1 |
| Triaridis, S | 1 |
| Andreadis, CG | 1 |
| Boukovinas, I | 1 |
| Koloutsos, GE | 1 |
| Teleioudis, Z | 2 |
| Kitikidou, K | 1 |
| Paraskevopoulos, P | 1 |
| Zervas, K | 2 |
| Antoniades, K | 1 |
| Crawford, BS | 1 |
| McNulty, RM | 1 |
| Kraut, EH | 1 |
| Turowski, RC | 1 |
| Senel, FC | 1 |
| Kadioglu Duman, M | 1 |
| Muci, E | 1 |
| Cankaya, M | 1 |
| Pampu, AA | 1 |
| Ersoz, S | 1 |
| Gunhan, O | 1 |
| Kotecha, RS | 1 |
| Powers, N | 1 |
| Lee, SJ | 1 |
| Murray, KJ | 1 |
| Carter, T | 1 |
| Cole, C | 1 |
| Otto, S | 1 |
| Schuler, K | 1 |
| Ihrler, S | 1 |
| Ehrenfeld, M | 1 |
| Mast, G | 1 |
| Oizumi, T | 1 |
| Funayama, H | 1 |
| Yamaguchi, K | 1 |
| Yokoyama, M | 1 |
| Takahashi, H | 1 |
| Yamamoto, M | 1 |
| Kuroishi, T | 1 |
| Kumamoto, H | 1 |
| Sasaki, K | 1 |
| Kawamura, H | 1 |
| Sugawara, S | 1 |
| Endo, Y | 1 |
| Treister, NS | 1 |
| Friedland, B | 1 |
| Göllner, M | 1 |
| Holst, S | 1 |
| Schmitt, J | 1 |
| Kraenzlin, ME | 1 |
| Graf, C | 1 |
| Meier, C | 1 |
| Kraenzlin, C | 1 |
| Friedrich, NF | 1 |
| Tanaka, Y | 1 |
| Koga, M | 1 |
| Yokomizo, Y | 1 |
| Inokuchi, S | 1 |
| Koga, C | 1 |
| Kusukawa, J | 1 |
| Scoletta, M | 1 |
| Arduino, PG | 1 |
| Dalmasso, P | 1 |
| Broccoletti, R | 1 |
| Mozzati, M | 1 |
| Ficarra, G | 1 |
| Beninati, F | 1 |
| López-Jornet, P | 2 |
| Camacho-Alonso, F | 2 |
| Molina-Miñano, F | 2 |
| Gómez-García, F | 2 |
| Vicente-Ortega, V | 2 |
| Gimsing, P | 1 |
| Carlson, K | 1 |
| Fayers, P | 1 |
| Waage, A | 1 |
| Mylin, A | 1 |
| Gluud, C | 1 |
| Juliusson, G | 1 |
| Hjorth-Hansen, H | 1 |
| Nesthus, I | 1 |
| Dahl, IM | 1 |
| Westin, J | 1 |
| Nielsen, JL | 1 |
| Knudsen, LM | 1 |
| Ahlberg, L | 1 |
| Hjorth, M | 1 |
| Andersen, NF | 1 |
| Linder, O | 1 |
| Wisløff, F | 1 |
| Aapro, M | 1 |
| Saad, F | 1 |
| Costa, L | 1 |
| Wehrhan, F | 1 |
| Hyckel, P | 1 |
| Amann, K | 1 |
| Ries, J | 1 |
| Schlegel, K | 1 |
| Neukam, F | 1 |
| Katz, J | 1 |
| Gong, Y | 1 |
| Salmasinia, D | 1 |
| Hou, W | 1 |
| Burkley, B | 1 |
| Ferreira, P | 1 |
| Casanova, O | 1 |
| Langaee, TY | 1 |
| Moreb, JS | 1 |
| Pozzi, S | 1 |
| Alloh Amichia, YC | 1 |
| Le Bars, P | 1 |
| Giumelli, B | 1 |
| Soueidan, A | 1 |
| Nicolatou-Galitis, O | 1 |
| Papadopoulou, E | 1 |
| Sarri, T | 1 |
| Boziari, P | 1 |
| Karayianni, A | 1 |
| Kyrtsonis, MC | 1 |
| Repousis, P | 1 |
| Barbounis, V | 1 |
| Migliorati, CA | 2 |
| Ngamphaiboon, N | 1 |
| Frustino, JL | 1 |
| Kossoff, EB | 1 |
| Sullivan, MA | 1 |
| O'Connor, TL | 1 |
| Martínez-Canovas, A | 1 |
| Cella, L | 1 |
| Oppici, A | 1 |
| Arbasi, M | 1 |
| Moretto, M | 1 |
| Piepoli, M | 1 |
| Vallisa, D | 1 |
| Zangrandi, A | 1 |
| Di Nunzio, C | 1 |
| Cavanna, L | 1 |
| Giro, G | 1 |
| Kajiya, M | 1 |
| Ohta, K | 1 |
| Almazrooa, S | 1 |
| Alshwaimi, E | 1 |
| Nishimura, I | 1 |
| Kawai, T | 1 |
| Bartl, R | 1 |
| Thumbigere-Math, V | 1 |
| Tu, L | 1 |
| Huckabay, S | 1 |
| Dudek, AZ | 1 |
| Lunos, S | 1 |
| Basi, DL | 1 |
| Hughes, PJ | 1 |
| Leach, JW | 1 |
| Swenson, KK | 1 |
| Gopalakrishnan, R | 1 |
| Leblicq, C | 1 |
| Laverdière, C | 1 |
| Décarie, JC | 1 |
| Delisle, JF | 1 |
| Isler, MH | 1 |
| Moghrabi, A | 1 |
| Chabot, G | 1 |
| Alos, N | 1 |
| Ducassou, S | 1 |
| Pérel, Y | 1 |
| Marx, RE | 2 |
| Tarassoff, P | 1 |
| Csermak, K | 1 |
| Carter, GD | 1 |
| Goss, AN | 2 |
| Greenberg, MS | 1 |
| Abe, M | 1 |
| Minoguchi, M | 1 |
| Jinbo, J | 1 |
| Kikuchi, Y | 1 |
| Chiba, A | 1 |
| Shibata, Y | 1 |
| Kogo, Y | 1 |
| Gralow, J | 1 |
| Carter, G | 1 |
| Doecke, C | 1 |
| Guarino, MJ | 1 |
| Hill, CE | 1 |
| Patel, K | 1 |
| Jimenez-Soriano, Y | 1 |
| Bagan, JV | 1 |
| Katz, M | 1 |
| Crowley, J | 1 |
| Hande, K | 1 |
| Makani, S | 1 |
| Mander, C | 1 |
| Cox, M | 1 |
| Wragg, K | 1 |
| Sarathy, AP | 1 |
| Bourgeois, SL | 1 |
| Goodell, GG | 1 |
| Merigo, E | 2 |
| Manfredi, M | 2 |
| Meleti, M | 2 |
| Corradi, D | 2 |
| Vescovi, P | 2 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Bamias, A | 1 |
| Kastritis, E | 1 |
| Bamia, C | 1 |
| Moulopoulos, LA | 1 |
| Melakopoulos, I | 1 |
| Bozas, G | 1 |
| Koutsoukou, V | 1 |
| Gika, D | 1 |
| Anagnostopoulos, A | 1 |
| Papadimitriou, C | 1 |
| Abi Najm, S | 1 |
| Lysitsa, S | 1 |
| Carrel, JP | 1 |
| Lesclous, P | 1 |
| Lombardi, T | 1 |
| Samson, J | 1 |
| Vastag, B | 1 |
| Zarychanski, R | 1 |
| Elphee, E | 1 |
| Walton, P | 1 |
| Johnston, J | 1 |
| Pastor-Zuazaga, D | 1 |
| Garatea-Crelgo, J | 1 |
| Martino-Gorbea, R | 1 |
| Etayo-Pérez, A | 1 |
| Sebastián-López, C | 1 |
| Robb-Nicholson, C | 1 |
| Nguyen, T | 1 |
| Zacharin, MR | 2 |
| Hay, KD | 1 |
| Bishop, PA | 1 |
| Alexander, RE | 1 |
| Farrar, SK | 1 |
| Thakkar, SG | 1 |
| Isada, C | 1 |
| Smith, J | 1 |
| Karam, MA | 1 |
| Reed, J | 1 |
| Tomford, JW | 1 |
| Englund, K | 1 |
| Richmond, M | 1 |
| Licata, A | 1 |
| Hatch, C | 1 |
| Hussein, MA | 1 |
| Dimitrakopoulos, I | 1 |
| Magopoulos, C | 1 |
| Karakasis, D | 1 |
| Siegel, MA | 1 |
| Elting, LS | 1 |
| Neumann, B | 1 |
| Grigg, AP | 1 |
| Shuttleworth, P | 1 |
| Reynolds, J | 1 |
| Schwarer, AP | 1 |
| Szer, J | 1 |
| Bradstock, K | 1 |
| Hui, C | 1 |
| Herrmann, R | 1 |
| Ebeling, PR | 1 |
| Banti, A | 1 |
| Mihou, D | 1 |
| Krikelis, D | 1 |
| Weeda, LW | 1 |
| Kademani, D | 1 |
| Koka, S | 1 |
| Lacy, MQ | 1 |
| Wutzl, A | 1 |
| Eisenmenger, G | 1 |
| Hoffmann, M | 1 |
| Czerny, C | 1 |
| Moser, D | 1 |
| Pietschmann, P | 1 |
| Ewers, R | 1 |
| Baumann, A | 1 |
| Treister, N | 1 |
| Nastro, E | 1 |
| Musolino, C | 1 |
| Allegra, A | 1 |
| Oteri, G | 1 |
| Cicciù, M | 1 |
| Alonci, A | 1 |
| Quartarone, E | 1 |
| Alati, C | 1 |
| Anguita C, T | 1 |
| Agurto P, J | 1 |
| Roa E, I | 1 |
| Laissle C, G | 1 |
| Guidotti, R | 1 |
| Ripasarti, A | 1 |
| Zanzucchi, E | 1 |
| D'Aleo, P | 1 |
| Corcione, L | 1 |
| Sesenna, E | 1 |
| Ferrari, S | 2 |
| Poli, T | 2 |
| Bonaninil, M | 1 |
| Dannemann, C | 1 |
| Grätz, KW | 1 |
| Riener, MO | 1 |
| Zwahlen, RA | 1 |
| Choi, JY | 1 |
| Kim, HJ | 1 |
| Lee, YC | 1 |
| Cho, BO | 1 |
| Seong, HS | 1 |
| Cho, M | 1 |
| Kim, SG | 1 |
| Clarke, BM | 1 |
| Boyette, J | 1 |
| Vural, E | 1 |
| Suen, JY | 1 |
| Anaissie, EJ | 1 |
| Stack, BC | 1 |
| Corso, A | 1 |
| Varettoni, M | 1 |
| Zappasodi, P | 1 |
| Klersy, C | 1 |
| Mangiacavalli, S | 1 |
| Pica, G | 1 |
| Lazzarino, M | 1 |
| Montebugnoli, L | 1 |
| Felicetti, L | 1 |
| Gissi, DB | 1 |
| Pizzigallo, A | 1 |
| Pelliccioni, GA | 1 |
| Marchetti, C | 1 |
| Shenker, NG | 1 |
| Jawad, AS | 1 |
| Ruan, M | 1 |
| Ji, T | 1 |
| Zhang, CP | 1 |
| Jadu, F | 1 |
| Lee, L | 1 |
| Pharoah, M | 1 |
| Reece, D | 1 |
| Wang, L | 1 |
| Engroff, SL | 1 |
| Kim, DD | 1 |
| Vieillard, MH | 1 |
| Maes, JM | 1 |
| Penel, G | 1 |
| Facon, T | 1 |
| Magro, L | 1 |
| Bonneterre, J | 1 |
| Cortet, B | 1 |
| Murray, DJ | 1 |
| Vesely, MJ | 1 |
| Novak, CB | 1 |
| Irish, J | 1 |
| Crump, M | 1 |
| Neligan, PC | 1 |
| Brown, JJ | 1 |
| Ramalingam, L | 1 |
| Abu-Id, MH | 1 |
| Warnke, PH | 1 |
| Gottschalk, J | 1 |
| Springer, I | 1 |
| Wiltfang, J | 1 |
| Acil, Y | 1 |
| Russo, PA | 1 |
| Kreusch, T | 1 |
| Bianchi, ML | 1 |
| Limonta, C | 1 |
| Frasunkiewicz, J | 1 |
| Biggioggero, M | 1 |
| Vai, S | 1 |
| Bedogni, A | 1 |
| Blandamura, S | 1 |
| Lokmic, Z | 1 |
| Palumbo, C | 1 |
| Ragazzo, M | 1 |
| Ferrari, F | 1 |
| Tregnaghi, A | 1 |
| Pietrogrande, F | 1 |
| Procopio, O | 1 |
| Saia, G | 1 |
| Ferretti, M | 1 |
| Bedogni, G | 1 |
| Chiarini, L | 1 |
| Ferronato, G | 1 |
| Ninfo, V | 1 |
| Lo Russo, L | 1 |
| Lo Muzio, L | 1 |
| Nocini, PF | 1 |
| Kohno, N | 1 |
| Wessel, JH | 1 |
| Dodson, TB | 1 |
| Zavras, AI | 1 |
| Sari, E | 1 |
| Bulut, N | 1 |
| Altundag, K | 1 |
| Landesberg, R | 1 |
| Cozin, M | 1 |
| Cremers, S | 1 |
| Woo, V | 1 |
| Kousteni, S | 1 |
| Sinha, S | 1 |
| Garrett-Sinha, L | 1 |
| Raghavan, S | 1 |
| Bianchi, B | 1 |
| Savi, A | 1 |
| Multinu, A | 1 |
| Balestreri, A | 1 |
| Ferri, A | 1 |
| Gueiros, LA | 1 |
| Lopes, MA | 1 |
| Leão, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Bone Marker Assessment of Multiple Myeloma Patients Treated With AminoBisphosphonates[NCT00577642] | Phase 2 | 29 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.[NCT00376883] | Phase 3 | 500 participants | Interventional | 2000-01-31 | Completed | ||
| Development Of A Predictive Score For Maxillary Osteochimionecrosis After Invasive Oral Surgery In Patients Treated Whith Biphosphonates Or Biotherapies: The PREV-ONM Study[NCT04257721] | 45 participants (Actual) | Observational | 2019-10-10 | Terminated (stopped due to rate of inclusions too low) | |||
| Conservative Versus Surgical Treatment for Medication Related Osteonecrosis of the Jaws (MRONJ) Stages I and II, a Quasi-experimental Clinical Trial With Discovery of Salivary Biomarkers[NCT04584840] | 50 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | |||
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for pamidronate and Osteonecrosis
| Article | Year |
|---|---|
Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review.
Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservati | 2019 |
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Fe | 2016 |
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Bone Density C | 2008 |
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac | 2009 |
Osteonecrosis or metastases of the jaw or both? Case report and review of the literature.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Dipho | 2010 |
Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injectio | 2007 |
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
Topics: Acute-Phase Reaction; Bone Diseases; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Multiple | 2011 |
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chem | 2005 |
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Dental Care for Chronically | 2006 |
Bisphosphonates and avascular necrosis of the mandible: case report and review of the literature.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Male; Mandibular Diseases; Middle Aged; Mu | 2008 |
Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2008 |
7 trials available for pamidronate and Osteonecrosis
| Article | Year |
|---|---|
Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study.
Topics: Aged; Bone Density Conservation Agents; Bone Marrow; Contrast Media; Diphosphonates; Female; Follow- | 2010 |
Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Alendronate; Antineoplastic Combined Chem | 2010 |
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation A | 2010 |
Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia.
Topics: Adolescent; Arthralgia; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; F | 2013 |
Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes.
Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Diphosphonates | 2006 |
Pamidronate reduces bone loss after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Bone Density; Bone Remodeling; Cyclosporine; Diphosphonates; Female; Glucoc | 2006 |
Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Analysis of Variance; Anti-Bacterial Agents; Bo | 2007 |
101 other studies available for pamidronate and Osteonecrosis
| Article | Year |
|---|---|
Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
Topics: Adolescent; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Ch | 2022 |
Comment on: "Team approach: Management of osteonecrosis in children with acute lymphoblastic leukemia: An ounce of prevention is worth a pound of cure: Consideration of prophylactic pamidronate.
Topics: Acute Disease; Child; Humans; Osteonecrosis; Pamidronate; Precursor Cell Lymphoblastic Leukemia-Lymp | 2021 |
Pamidronate Disodium Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells In Vitro.
Topics: Cells, Cultured; Diphosphonates; Humans; Mandible; Mesenchymal Stem Cells; Osteogenesis; Osteonecros | 2017 |
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Ja | 2018 |
Elderly man with mandibular pain.
Topics: Abscess; Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Drainage; Fever; Humans; Mal | 2019 |
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
Topics: Administration, Intravenous; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Combin | 2013 |
Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study.
Topics: Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Cell Adhesion; Diphosphonates; Drug-Rel | 2013 |
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Bone | 2014 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Fem | 2015 |
Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws.
Topics: Aged; Antineoplastic Agents; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans | 2016 |
Bisphosphonate-associated osteonecrosis of the jaw: successful treatment at 2-year follow-up.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Debrideme | 2008 |
Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Femal | 2008 |
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous | 2008 |
Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Topics: Aged, 80 and over; Alveolar Bone Loss; Antineoplastic Agents; Bone Density Conservation Agents; Diph | 2008 |
Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Child; Child, Preschool; Diphosphonates; Female; Follow | 2008 |
Numb chin syndrome by biphosphonates.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Chin; Diphosphonates; Female; Humans; Hype | 2008 |
Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Chronic | 2009 |
[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Multiple Myeloma; Oral Hy | 2009 |
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Angiogenesis Inhibitors; Anti-Bac | 2009 |
Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Femal | 2009 |
Paget's disease of bone and osteonecrosis.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Dry Socket; Female; Humans; Hypercementosis; | 2009 |
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis | 2009 |
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Di | 2010 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; | 2009 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2009 |
Jaw bone changes in rats after treatment with zoledronate and pamidronate.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Femur; Im | 2010 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern | 2010 |
Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diphospho | 2010 |
Prosthodontic treatment of a patient with bisphosphonate-induced osteonecrosis of the jaw using a removable dental prosthesis with a heat-polymerized resilient liner: a clinical report.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Denture Liners; Denture, Partial, Removable; | 2010 |
Possible beneficial effect of bisphosphonates in osteonecrosis of the knee.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density Conservation Agents; Bone Marrow Diseas | 2010 |
[A case of breast cancer with extensive osteonecrosis of maxilla induced by a bisphosphonate].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Maxil | 2010 |
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study.
Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chroni | 2010 |
An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats.
Topics: Animals; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Drug Combinations; Glucoco | 2010 |
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Bre | 2010 |
Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
Topics: Alkaline Phosphatase; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Morphogen | 2011 |
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Bone Density Conservation Agents; Cohort Studies; Collag | 2011 |
[Prosthetic rehabilitation after osteonecrosis of the jaws due to histiocytosis X and treatment with bisphosphonates apropos of a case].
Topics: Adult; Alendronate; Bone Density Conservation Agents; Denture Design; Denture, Partial, Fixed; Dentu | 2010 |
Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Co | 2011 |
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anti | 2011 |
Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bone Density Conservation Agents; Dexamethas | 2011 |
Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw.
Topics: Aged; Diphosphonates; Female; Humans; Injections, Intralesional; Jaw Diseases; Osteonecrosis; Osteop | 2011 |
A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw.
Topics: Animals; Anti-Bacterial Agents; Apoptosis; Bone Density Conservation Agents; Cell Movement; Cell Sur | 2011 |
[Inflammation of the jaws during treatment with bisphosphonates].
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseas | 2011 |
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Injections, | 2012 |
Curing acute lymphoblastic leukemia and avoiding osteonecrosis: can't we have it all?
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Male; Osteonecrosis; Pamidronate; | 2013 |
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat | 2003 |
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat | 2003 |
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat | 2003 |
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat | 2003 |
Avascular necrosis of the jaws: risk factors in metastatic cancer patients.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecros | 2003 |
Bisphosphonates and avascular necrosis of the jaws.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Tooth Extraction; Zole | 2003 |
Intravenous bisphosphonates and osteonecrosis.
Topics: Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Interdisciplinary Communication; Jaw Di | 2004 |
[Gaucher disease with multiple bone necrosis treated by enzyme replacement therapy and pamidronate].
Topics: Adult; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Gaucher Disea | 2004 |
[Rapid drug information].
Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Info | 2005 |
Bisphosphonates and avascular necrosis of the jaw: a possible association.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents; Diphosphonates; Female; Follow-Up St | 2005 |
Bisphosphonates, cancer, and osteonecrosis--a single practice experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Int | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; | 2005 |
Studies in osteonecrosis.
Topics: Antineoplastic Agents; Diphosphonates; Humans; Imidazoles; Osteonecrosis; Pamidronate; Zoledronic Ac | 2005 |
Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Disease | 2005 |
Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
Topics: Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Curettage; Diphosphon | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neopla | 2005 |
[Bisphosphonates-related jaw osteonecrosis].
Topics: Adolescent; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Human | 2005 |
Consumer groups look to improve adverse event reporting systems.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Bone Density Conservation Agents; Co | 2005 |
Osteonecrosis of the jaw associated with pamidronate therapy.
Topics: Actinomycosis; Antineoplastic Agents; Diphosphonates; Female; Humans; Male; Mandible; Neoplasms; Ost | 2006 |
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalce | 2006 |
[Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates].
Topics: Aged; Alendronate; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular D | 2005 |
By the way, doctor. I've heard that taking Fosamax for a long time causes the jawbone to deteriorate. Do you know anything about this?
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Osteoclas | 2005 |
Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
Topics: Adenocarcinoma; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma; Diabetes Mellitus, T | 2006 |
Relationship between periodontal disease and systemic diseases.
Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Dental Implantation, Endosseous; D | 2006 |
The buzz about bisphosphonates.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Midd | 2006 |
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; | 2006 |
[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Mult | 2006 |
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.
Topics: Aged; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Jaw Diseases; Male; M | 2006 |
Drug induced osteonecrosis of the jaws.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density; Bone Densit | 2006 |
Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazole | 2006 |
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Topics: Adult; Aged; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fol | 2006 |
Images in clinical medicine. Bisphosphonate-associated osteonecrosis of the jaw.
Topics: Anti-Infective Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorh | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2007 |
[Osteonecrosis associated with the use of biphosphonates: Case report].
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Disease | 2006 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conserv | 2006 |
I'm taking bisphosphonates for my osteoporosis, but I've heard it can cause a serious jaw condition. Is this something I should be concerned about?
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonec | 2006 |
Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.
Topics: Adult; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Disea | 2007 |
Inhibition of bone healing by pamidronate in calvarial bony defects.
Topics: Absorbable Implants; Animals; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Dip | 2007 |
Bisphosphonates and jaw osteonecrosis: the UAMS experience.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Bone Density Conservation Agents; Curettage; Dental | 2007 |
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
Topics: Aged; Diphosphonates; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imidazoles; Inc | 2007 |
Bisphosphonates and osteonecrosis of the jaw.
Topics: Bone Remodeling; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Neoplasms; Osteonecrosis; Osteopo | 2007 |
[Advances in the research of bisphosphonate-associated osteonecrosis of the jaws].
Topics: Alendronate; Biomedical Research; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density C | 2006 |
A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients.
Topics: Diphosphonates; Humans; Incidence; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Radio | 2007 |
Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction?
Topics: Bone Density Conservation Agents; Bone Plates; Bone Transplantation; Breast Neoplasms; Carcinoma; Di | 2007 |
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; M | 2008 |
Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Topics: Adolescent; Bone Density Conservation Agents; Child; Cohort Studies; Diphosphonates; Humans; Imidazo | 2008 |
"Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphona | 2008 |
Comment on: Bisphosphonates and osteonecrosis of the jaw.
Topics: Administration, Oral; Adolescent; Adult; Alendronate; Child; Child, Preschool; Diphosphonates; Dose- | 2008 |
Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphospho | 2008 |
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Case-Control Studies; Co | 2008 |
Osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Jaw Dis | 2008 |
Bisphosphonate-associated osteonecrosis. A clinician's reference to patient management.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Conservation Ag | 2008 |
Inhibition of oral mucosal cell wound healing by bisphosphonates.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Caspase 3; Cell Proliferation; Cells, Cultured | 2008 |
Fibula free flap with endosseous implants for reconstructing a resected mandible in bisphosphonate osteonecrosis.
Topics: Aged; Bone Density Conservation Agents; Bone Transplantation; Dental Implantation, Endosseous; Dipho | 2008 |
Paget's disease and bisphosphonate-associated osteonecrosis of the jaws.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, | 2008 |